Harvard Bioscience Updates Investors on Q1 Results, Debt Refinancing, and Strategic Consolidation

summarizeSummary

Harvard Bioscience released an investor presentation detailing Q1 2026 results, the specifics of its debt refinancing, and a strategic manufacturing consolidation plan expected to significantly boost future EBITDA.

check_boxKey Events

• Q1 2026 Financials

  Revenue declined to $20.8 million, but diluted loss per share improved to $(0.77) and gross margin increased to 58%. Cash flow from operations remained negative at $(12.2) million.

• FY26 Outlook

  The company projects 2-4% revenue growth and 6-10% adjusted EBITDA growth for fiscal year 2026.

• Debt Refinancing Details

  The recent debt refinancing includes convertible notes at $10.00/share and warrants for 200,000 shares at $5.00/share, extending debt maturity to 2029 and generating $3 million in annual cash savings.

• Manufacturing Consolidation

  "Project Viking" aims to consolidate manufacturing by Q1 2027, with projected adjusted EBITDA improvements of $3 million in 2027 and $4 million in 2028 and beyond.

auto_awesomeAnalysis

This investor presentation provides a comprehensive update on Harvard Bioscience's financial performance and strategic initiatives. It details the Q1 2026 results, which show improved diluted loss per share and gross margin despite a revenue decline and negative cash flow. Crucially, the filing outlines the specifics of the recent debt refinancing, including convertible notes and warrants, which extended debt maturity and are expected to generate $3 million in annual cash savings. Furthermore, it elaborates on the "Project Viking" manufacturing consolidation, projecting significant adjusted EBITDA improvements of $3 million in 2027 and $4 million in 2028 and beyond. These operational and financial restructuring efforts are critical for a company of this size, aiming to improve long-term profitability and address previous financial concerns.